Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07415954 · ClinicalTrials.gov registry record · Phase 2
A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes
A Phase 2 study, sponsored by Novo Nordisk A/S.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 270
- Enrollment target
NCT07415954 is a Phase 2 study that is actively recruiting participants, run by Novo Nordisk A/S. The registered enrollment target is 270 participants.
The verdict
NCT07415954, a Phase 2 study, is actively recruiting participants, sponsored by Novo Nordisk A/S.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 270 participants
- Enrollment target
Study Summary
This study is being done to look at the effect and safety of different doses of NNC0662-0419 in people living with type 2 diabetes when compared to placebo or semaglutide. The purpose of this clinical study is to find out if NNC0662-0419 is effective and safe for treating people living with type 2 diabetes. Participants will get either NNC0662-0419, semaglutide or placebo. Which treatment participants get is decided by chance. NNC0662-0419 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Semaglutide is an approved medication to treat type 2 diabetes.
Interventions
- DRUG Placebo
- DRUG Semaglutide
- DRUG NNC0662-0419
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2026-04-17 |
| Est. Completion | 2027-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07415954
The ClinicalTrials.gov registry entry for NCT07415954 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 270 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07415954 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07415954 about?
NCT07415954 is a clinical study titled "A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes". This study is being done to look at the effect and safety of different doses of NNC0662-0419 in people living with type 2 diabetes when compared to placebo or semaglutide. The purpose of this clinical study is to find out if NNC0662-0419 is effective and safe for treating people living with type 2 d...
What is the current status of trial NCT07415954?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 270 participants. The study started on 2026-04-17. Estimated completion is 2027-10-01.
What interventions are being tested in trial NCT07415954?
The interventions under investigation include: Placebo (DRUG), Semaglutide (DRUG), NNC0662-0419 (DRUG).
Who is sponsoring clinical trial NCT07415954?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.